TY - JOUR T1 - The impact of different antibiotic treatment regimens on mortality in <em>Mycobacterium avium</em> complex pulmonary disease (MAC-PD): A population-based cohort study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01875-2019 SP - 1901875 AU - Sarah K. Brode AU - Hannah Chung AU - Michael A. Campitelli AU - Jeffrey C. Kwong AU - Rinku Sutradhar AU - Alex Marchand-Austin AU - Kevin L. Winthrop AU - Frances B. Jamieson AU - Theodore K. Marras Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/04/08/13993003.01875-2019.abstract N2 - Evidence-based guidelines recommend the combination of macrolide-ethambutol-rifamycin as first-line treatment for Mycobacterium avium complex pulmonary disease (MAC-PD) [1]. Whether this regimen results in improved survival is unknown.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Brode reports grants from Insmed Pharmaceuticals, personal fees from Boehringer Ingelheim, personal fees from Astra-Zeneca , grants from Canadian Institutes of Health Research (CIHR), outside the submitted work.Conflict of interest: Ms. Chung has nothing to disclose.Conflict of interest: Mr. Campitelli has nothing to disclose.Conflict of interest: Dr. Kwong has nothing to disclose.Conflict of interest: Dr. Sutradhar has nothing to disclose.Conflict of interest: Mr. Marchand-Austin has nothing to disclose.Conflict of interest: Dr. Winthrop reports grants and personal fees from Insmed, personal fees from Johnson &amp;amp; Johnson, personal fees from Paratek , personal fees from Red Hill Biopharma, personal fees from Horizon, outside the submitted work.Conflict of interest: Dr. Jamieson has nothing to disclose.Conflict of interest: Dr. Marras reports grants and personal fees from Insmed, personal fees from Astra-Zeneca, personal fees from Horizon, personal fees from RedHill, personal fees from France Foundation, personal fees from Novartis, outside the submitted work. ER -